DBV TECHNOLOGIE/S ADR (NASDAQ:DBVT) has been mauled in recent action. But it hasn’t been a spectacular decline, which is all the more frustrating and frightening for shareholders. The move lower has been gradual. The stock has matriculated down the chart in a series of staircase steps. All of that follows the cliff dive you see back in October of last year, when the company missed its primary endpoint in a key Phase 3 trial and fell nearly 50% in a single day.
This week, DBVT announced that three oral abstracts supporting the therapeutic potential of Viaskin Peanut were presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2018 Annual Scientific Meeting in Seattle, Washington, November 15-19, 2018. According to the release, the presentations included additional analyses from PEPITES, a pivotal Phase III efficacy and safety study of Viaskin Peanut in children ages four to 11. All abstracts are available online on the ACAAI Meeting website.
DBV TECHNOLOGIE/S ADR (NASDAQ:DBVT) frames itself as a clinical-stage biopharmaceutical company that engages in the research and development of epicutaneous immunotherapy products.
Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow’s milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy; and booster vaccine for Bordatella pertussis.
Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn’s disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers.
DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
Where is the Bottom?
As we discussed earlier, DBVT recently announced that three oral abstracts supporting the therapeutic potential of Viaskin Peanut were presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2018 Annual Scientific Meeting in Seattle, Washington, November 15-19, 2018.
The stock has suffered a bit of late, with shares of DBVT taking a hit in recent action, down about -7% over the past week.
Dr. Hugh Sampson, Chief Scientific Officer of DBV Technologies and Kurt Hirschhorn Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai said, “The breadth of data we shared with the scientific and medical community at ACAAI further illustrate the therapeutic benefit children may receive from treatment with Viaskin Peanut. From an analysis showing a robust overall patient desensitization to a quantitative model suggesting that patients treated with Viaskin Peanut in PEPITES may experience a meaningful reduction of the risks associated with accidental exposure, we are continuing to see important evidence supporting the potential use of Viaskin Peanut in the treatment of peanut allergy.”
DBV TECHNOLOGIE/S ADR (NASDAQ:DBVT) had no reported sales in its last quarterly financial data. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($202.2M against $34.9M).